Starpharma Holdings (SPHRF) 0.6450 $SPHRF Herpes Simplex

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Starpharma Holdings (SPHRF) 0.6450 $SPHRF

Herpes Simplex Infections Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ttlczd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - Adamis Pharmaceuticals Corporation - Admedus Ltd - Agenus, Inc. - AiCuris GmbH & Co. KG - AlphaVax, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - BioApex, s.r.o. - CEL-SCI Corporation - Chimerix, Inc. - Colby Pharmaceutical Company - Epiphany Biosciences, Inc. - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - GenVec, Inc. - Immune Design Corp. - Immunovaccine, Inc. - Kala Pharmaceuticals, Inc. - Mymetics Corporation - NanoBio Corporation - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Onxeo SA - Oryzon Genomics S.A. - Osel Inc. - PaxVax - Peregrine Pharmaceuticals, Inc. - Profectus BioSciences, Inc. - Romark Laboratories, L.C. - Sanofi - Sanofi Pasteur SA - Spider Biotech - Starpharma Holdings Limited - Vaccibody AS For more information visit http://www.researchandmarkets.com/research/tt...es_simplex
IMDZ: 24.04 (+3.00), CVM: 0.67 (+0.04), FOMX: 11.18 (+0.22), ADMP: 4.08 (+0.08), GNCA: 14.39 (+0.15), NNVC: 1.56 (-0.04), CMRX: 46.90 (+1.08)

Starpharma Holdings Limited - Product Pipeline Review - 2014
M2 - Wed Jun 10, 3:25AM CDT
Product Pipeline Review - 2014

Viral Conjunctivitis Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/22rgnh/viral) has announced the addition of the "Viral Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Foresight Biotherapeutics, Inc. - NanoViricides, Inc. - NovaBay Pharmaceuticals, Inc. - Panoptes Pharma Ges.m.b.H. - Starpharma Holdings Limited Drug Profiles - astodrimer - EKCCide-I - FST-100 - NVC-638 - NVC-704 - NVC-727 - PP-001 For more information visit http://www.researchandmarkets.com/research/22rgnh/viral
NNVC: 1.56 (-0.04)

Genital Herpes Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Mon Jun 08, 10:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k7sxzp/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Agenus, Inc. - AiCuris GmbH & Co. KG - Foamix Pharmaceuticals Ltd. - Genocea Biosciences, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Vical Incorporated Drug Profiles - acyclovir - astodrimer - GEN-003 - genital herpes vaccine - genital herpes vaccine [HSV-2] - HerpeCide-I - herpes simplex vaccine - HSV [type 2] vaccine - pritelivir - VCLHB-01 - VCLHM-01 For more information visit http://www.researchandmarkets.com/research/k7...tal_herpes
VICL: 0.70 (unch), FOMX: 11.18 (+0.22), GNCA: 14.39 (+0.15), NNVC: 1.56 (-0.04)

Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT

PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81), SNY: 51.49 (+2.71)

Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 48.27 (+0.10)

Human Papillomavirus Infections - Pipeline Review, H2 2014
M2 - Fri Dec 19, 4:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/8sdzln/human) has announced the addition of the "Human Papillomavirus Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Agilvax - Beijing Minhai Biotechnology - Bharat Biotech International - Chong Kun Dang Pharmaceutical - Chongqing Zhifei Biological Products - Crucell - FluGen - Genticel - Immunservice - Indian Immunologicals - MediGene - Merck & Co - Nielsen Biosciences - Redbiotec - Selecta Biosciences - Shanghai Zerun Biotechnology - Spider Biotech - Starpharma Holdings - Takeda Pharmaceutical - Vaxart For more information visit http://www.researchandmarkets.com/research/8sdzln/human
MRK: 57.95 (+0.57)

Genital Herpes - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/wc7b5f/genital_herpes) has announced the addition of the "Genital Herpes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Genital Herpes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Vical Incorporated - Agenus, Inc. - NanoViricides, Inc. - Starpharma Holdings Limited - Foamix Ltd. - AiCuris GmbH & Co. KG For more information visit http://www.researchandmarkets.com/research/wc...tal_herpes
VICL: 0.70 (unch), NNVC: 1.56 (-0.04)

Nanotechnology - 2014 Global Strategic Business Report
M2 - Thu Oct 23, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6n85z6/nanotechnology) has announced the addition of the "Nanotechnology - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 411 companies including many key and niche players. This report analyzes the worldwide markets for Nanotechnology in US$ Billion by the following End-Use Sectors: - Chemicals - Automotive - Aerospace & Defense - Semiconductors & Electronics - Pharma & Healthcare - Food - Others Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Review Of Select Nanotechnology Based Product Markets 3. R&D Structure & Financing 4. Nanotech Patents - An Overview 5. Technology Overview 6. Techniques And Technologies 7. Nanotech Fears - Are They Justified? 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 411 (including Divisions/Subsidiaries - 424) - The United States (208) - Canada (11) - Japan (37) - Europe (131) - - France (7) - - Germany (54) - - The United Kingdom (28) - - Italy (3) - - Spain (1) - - Rest of Europe (38) - Asia-Pacific (Excluding Japan) (29) - Middle East (8) Companies Mentioned - Advanced Diamond Technologies, Inc. - Advanced Nano Products Co., Limited - Altair Nanotechnologies Inc. - Arrowhead Research Corporation - Bruker Corporation - Catalytic Materials, LLC - Chemat Technology Inc. - eSpin Technologies, Inc. - ELITech Group - Genefluidics, Inc., - Hanwha Nanotech Corporation - Hybrid Plastics - Hyperion Catalysis International, Inc. - Integran Technologies, Inc. - Intrinsiq Materials Limited - Life Technologies Corporation - Luxtera, Inc. - Nanocyl S.A. - NanoMaterials Ltd, - Nanosys, Inc. - QuantumSphere, Inc. - Raymor Industries, Inc. - Rogue Valley Microdevices, Inc. - Shenzhen Nanotech Port Co., Ltd. - SouthWest NanoTechnologies, Inc. - Starpharma Holdings - Teledyne Scientific & Imaging, LLC - Unidym, Inc. For more information visit http://www.researchandmarkets.com/research/6n...technology
LIFE: 18.36 (+3.03), ARWR: 6.68 (+0.07)

FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial
Business Wire - Mon Jul 14, 4:35AM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel(R) bacterial vaginosis (BV) product for the prevention of recurrent BV.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading